H.C. Wainwright reiterates Jade Biosciences stock rating at buy

H.C. Wainwright has reaffirmed its Buy rating for Jade Biosciences (NASDAQ:JBIO) stock and maintained its price target at $55.00, reflecting a potential 300% upside from the current $14.05 share price. Three analysts covering the stock continue to rate it Strong Buy, with price targets ranging from $40 to $77. At the 2026 European Academy of Dermatology and Venereology Congress, Jade Biosciences presented preclinical data on JADE301, a selective, half-life extended anti-interferon beta monoclonal antibody for dermatomyositis.

The company compared JADE301 to a dazukibart comparator in the same assays, finding JADE301 to have a dissociation constant of 11.3 pM, which is approximately 2.5-fold higher than the comparator's 28.1 pM. H.C. Wainwright analyst Arthur He stated that the company maintains its Buy rating and $55 price target for JBIO. The firm's cash position, which exceeds its debt, and a 54% return over the past year, as noted in InvestingPro Tips, have contributed to this rating.

However, the stock has declined 4.6% in the past week. Investors can access additional ProTips for more detailed analysis. Jade Biosciences has garnered analyst attention due to the presentation of preclinical data for JADE301 at the EADV conference, which showed a threefold increase in half-life compared to a competing drug. Analysts at Wedbush and Stifel have also reiterated their ratings and adjusted their price targets, citing the company's promising drug development program and potential improvements over existing treatments. Jade Biosciences plans to begin a Phase 1 study for JADE301 in the fourth quarter of 2026.